Immunosuppressive effect of adipose-derived stromal cells on imiquimod-induced psoriasis in mice

A potential role of mesenchymal stem cells derived from human umbilical cord blood in ameliorating psoriasis-like skin lesion in the rats

“…Psoriatic symptoms, higher expression of inflammatory mediators, and the infiltration of immune cells to the skin were all alleviated after MSC administration. This shows that the MSC infusion had immunomodulatory and anti-inflammatory effects, thereby strongly inhibiting the severity and development of psoriasis as reported by other studies like Rokunohe et al [35] who used adipose tissue derived MSCs, Owczarczyk-Saczonek et al [31] who used bone marrow derived MSCs, Imai et al [15] who used human amnion derived MSCs and Chen et al [6] who used human umbilical cord-derived MSCs. Th17 cell homeostasis is the relationship with Tregs, whose imbalance may lead to the development of psoriasis as described by Rafei et al [33] who confirmed that MSCs inhibit the activity of the Th 17 cell, reducing the expression of interleukin IL-17 and decreasing inflammatory cell infiltration in the central nervous system.…”

Metabolic Syndrome and Skin Diseases

“…Furthermore, ADMSCs therapy has been reported in both an imiquimod (IMQ)-induced psoriasis mouse model and in psoriasis patients. In the imiquimod-induced psoriasis mouse model, the intradermal administration of ADMSCs inhibits IL-17A and TNF-a, and suppresses the IMQ-induced inflammation (152). In psoriasis patients (five patients from three case reports), those who received the intravenous injection of ADMSCs, all showed great improvement of psoriatic erythema, scaling, and induration by significant decrease of PASI scores with no severe adverse events (153–155).…”

Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review

“…17 Only one preclinical study has been performed on ADSCs, which showed that IMQ-induced inflammatory changes are inhibited after intradermal injection of ADSC. 18 Human tonsil-derived MSCs were able to prevent Th17-mediated autoimmune response via regulation of the programmed death-1/programmed death ligand-1 pathway. 21 Moreover, Campanati et al recently confirmed the in vitro capability of dermal MSCs taken from healthy controls to revert the proinflammatory cytokine production by aberrant MSCs obtained from psoriatic plaques (p-MSCs) and to lower p-MSC proliferation rates when in coculture.…”